CYP2C19 and epilepsy: A recent population pharmacokinetic study in 287 Chinese patients with epilepsy showed that CYP2C9 in combination with CYP2C19 genotypes significantly influenced the pharmacokinetic variability of valproic acid, as quantified by population pharmacokinetic analysis [120].